Chuangyebang was informed that Shanghai, China – Yijie Like (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as “Yijie Like”) announced today that it has completed the angel round and the Pre-A round of financing, raising a total of more than 100 million yuan in funds. This round of financing was jointly completed by Morningside Ventures, Xicheng Jinrui, Sany Innovation and Taiyu Capital, and the angel round shareholder Source Capital continued to participate. This round of financing will be used to test the company’s own core epigenetic editing technology in non-human primates, expand and improve team capabilities, and support early clinical trials.
Yijielike is a cutting-edge biotechnology company dedicated to using unique epigenetic regulation technology to treat a variety of diseases. Its patented technology platform continuously explores through its artificial intelligence (AI) algorithms to obtain better CRISPR-Cas components, which can regulate target genes or control the expression of multiple genes simultaneously without changing the DNA sequence.
According to Yijierike, among similar technologies, the company’s technology platform does not require cutting DNA, so it can avoid potential risks, such as off-target effects, short half-life and poor patient compliance. Combined with the company’s own patented lipid nanoparticle (LNP) drug delivery system, Yijierike’s technology platform has been validated in in vivo and in vitro models of ophthalmic, neurological, metabolic and rare diseases, enabling precise drug delivery. Efficient delivery to target cells and tissues.
It is understood that epigenetic modification is a natural and heritable gene regulation mechanism in the human body that does not change the DNA sequence inherent in cells. Through the company’s proprietary technology platform, scientists are able to edit endogenous gene genetic expression pathways to precisely and efficiently deliver drugs to target tissues and cells, resulting in potent and long-lasting therapeutic effects. Yijielike has gathered a group of scientists and industry veterans to guide technology research and product development.
Dr. Baohong Zhang, co-founder and CEO of Yijie Like, said: “Epigenetic editing technology is an emerging and highly differentiated gene editing technology. With a deeper understanding and the ability to further explore the potential of this technology to treat a variety of diseases. With this funding, we will further develop the expanded team while validating the platform technology in animal models, accelerating lead product candidates from discovery to progress in clinical development.”
Xue Wenyu, Managing Director of Morningside Ventures, said, “Yijielike is unique among many gene editing therapy development companies. We are delighted to invest in Yijielike. We believe that the company can further explore and develop precision gene therapy, which will benefit the vast patient population. benefit from it.”
Chen Leiwen, managing partner of Xicheng Jinrui, said, “Compared with other gene therapy methods, epigenetic editing has more advantages in mechanism of action and can reversibly regulate gene expression levels, which will be the next frontier of genomics. We are delighted to support Yijierike in the development of innovative epigenetic editing treatments, providing new available tools and effective treatments for the medical field, and we look forward to bringing more innovative treatments to patients around the world.”
Dr. Wang Xukun, Partner of Sany Innovation, said, “Sany Innovation is very honored to participate in this round of financing of Yijie Rico. We have taken a solid step on the road from “new in China” to “new in the world”. We hope to continue to witness the clinical benefits of patients brought about by the company’s innovative technological breakthroughs in the future, and provide the necessary support for the company’s development from all aspects. support.”
Dr. Ji Tianrong, founder and general manager of Taiyu Investment, said, “Epigenetic editing, as a cutting-edge biotechnology for the next generation of gene therapy, can minimize off-target effects while exerting the therapeutic effect of gene editing, and has a high potential for finished drugs. , I hope this technology can bring good news to more patients.”
media coverage
Venture Capital TechWeb
Related events
- Gene editing company Yijielike completes angel round and Pre-A round of financing of more than 100 million yuan2022-08-08
- “Weiguang Gene” completed an angel round of financing of nearly 100 million yuan2022-06-13
- ” Yueer Gene ” received US$50 million in Series B financing2022-06-02
- Huida Gene completes hundreds of millions of C rounds of financing2022-05-13
- Qiheshengke completed a seed round of financing of over 100 million yuan2022-03-21
This article is reprinted from: https://readhub.cn/topic/8ihqsE1HXP5
This site is for inclusion only, and the copyright belongs to the original author.